Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Curanex Pharmaceuticals Inc. ( (CURX) ) is now available.
On August 27, 2025, Curanex Pharmaceuticals Inc closed its initial public offering, raising $15 million through the sale of 3,750,000 shares at $4.00 each. On September 12, 2025, the company announced that underwriters exercised their option to purchase an additional 562,500 shares, bringing total gross proceeds to $17.25 million. This move enhances Curanex’s financial position as it advances its lead drug candidate, Phyto-N, through clinical trials.
More about Curanex Pharmaceuticals Inc.
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company based in Jericho, New York, focusing on discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract with anti-inflammatory properties, targeting diseases such as ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
Average Trading Volume: 2,873,751
See more data about CURX stock on TipRanks’ Stock Analysis page.